Dr. Fischer has received consulting fees, speaker honoraria, and grant support from Boston Scientific, Impulse Dynamics, Medtronic, Spectranetics, and St. Jude Medical, and is currently employed by St. Jude Medical. The remaining authors report no conflicts of interest. No external funding.
The Impact of Transvenous Lead Extraction on Tricuspid Valve Function
Article first published online: 30 AUG 2013
©2013, The Authors. Journal compilation ©2013 Wiley Periodicals, Inc.
Pacing and Clinical Electrophysiology
Volume 37, Issue 1, pages 19–24, January 2014
How to Cite
COFFEY, J. O., SAGER, S. J., GANGIREDDY, S., LEVINE, A., VILES-GONZALEZ, J. F. and FISCHER, A. (2014), The Impact of Transvenous Lead Extraction on Tricuspid Valve Function. Pacing and Clinical Electrophysiology, 37: 19–24. doi: 10.1111/pace.12236
- Issue published online: 6 JAN 2014
- Article first published online: 30 AUG 2013
- Manuscript Accepted: 10 JUN 2013
- Manuscript Revised: 11 MAY 2013
- Manuscript Received: 2 FEB 2013
- Boston Scientific
- Impulse Dynamics
- St. Jude Medical
- lead extraction;
- device infection;
- device malfunction;
- tricuspid regurgitation;
- valvular heart disease;
- cardiac implantable electronic device
Few data exist regarding the effect of transvenous lead extraction (TLE) on tricuspid valve function. The objective of this study was to examine the effect of TLE on the development of postprocedure tricuspid regurgitation (TR).
To assess the impact of TLE on tricuspid valve function.
A single center retrospective analysis of consecutive patients referred for TLE between June 2006 and November 2011. Patients were included only if they underwent transthoracic echocardiography (TTE) before and after lead extraction (N = 124). Patients were assigned a preprocedure and postprocedure TR score on a continuous scale from 0 to 6 (0 = none, 1 = trace, 2 = mild, 3 = mild/moderate, 4 = moderate, 5 = moderate/severe, and 6 = severe). A clinically significant increase in TR was defined as both (1) an increase in TR score of at least two points, and (2) a postprocedure TR score ≥4 (moderate).
A total of 124 patients referred for TLE underwent a TTE both before (9 ±16 months) and after lead extraction (4 ± 8 months). A total of 200 leads (1.6 ± 0.8 per patient) were extracted. The mean change in TR score after lead extraction was +0.18 (95% confidence interval [CI] −0.03 to 0.39, P = 0.11). A clinically significant increase in TR occurred in 7/124 (5.6% [CI 2.3–11.3%]) patients. Age ≥75 (+0.45, [CI 0.07–0.84, P = 0.02]), removal of ≥2 leads (+0.40 [CI 0–0.81, P = 0.05]), and powered sheath-assisted extraction (+0.34 [CI 0.05–0.62, P = 0.02]) were significantly associated with an increase in TR score.
TLE is rarely associated with the development of clinically significant TR. In our cohort, patient age ≥75 years, pacemaker as opposed to ICD, and removal of ≥2 leads predicted worsening TR.